Skip to main content
. 2020 Dec 23;44(6):802–818. doi: 10.4093/dmj.2020.0258

Fig. 3.

Fig. 3

Choice of anti-obesity drugs based on obesity-associated comorbidities. BMI, body mass index; CVD, cardiovascular disease; NASH, non-alcoholic steatohepatitis; PCOS, polycystic ovary syndrome. aIncrease heart rate.